Abstract
ObjectiveTo investigate the efficacy and safety of transarterial embolization (TAE) using embolization microspheres in the treatment of non-hypervascular malignant liver tumors.MethodsPatients with malignant non-hypervascular liver tumors, who were treated with TAE using embolization microspheres, were selected and analyzed retrospectively. The technical success rate, tumor response, and complications were assessed.ResultsSix patients were included in the study: 1 patient each with hepatocellular-cholangiocarcinoma, intrahepatic cholangiocarcinoma, hepatic metastasis after resection of common bile duct carcinoma, liver metastasis from colon cancer, liver metastasis from esophageal cancer, and liver metastasis from pancreatic cancer. The technical success rate was 100%. At 1 and 3 months after TAE, tumor local reactions were seen in 6/6 and 2/6 patients, respectively, and the tumor necrosis rates were 48%-73% and 22%-68%, respectively. The main complications were those related to the embolization syndrome, including 1 case of liver abscess and 1 case of severe pain on the first day after embolization.ConclusionTAE with embolization microspheres is safe and effective in non-hypervascular liver tumors. It is a feasible option for palliative therapy of these tumors.
Highlights
Malignant tumor of the liver, which includes primary and secondary liver cancers, are a relatively common form of malignancy
Local ablation treatment is mainly applied in solid tumors of relatively small size (
Patients were eligible for inclusion if they had 1) a confirmed non-hypervascular malignant tumor of liver, and were unwilling or unsuitable for surgery; 2) TMGs only was applied during the embolization, no other embolic agents such as iodized oil, gelatin sponge and so on
Summary
Malignant tumor of the liver, which includes primary and secondary liver cancers, are a relatively common form of malignancy. A considerable proportion of patients have inoperable disease and require minimally invasive treatments, such as transarterial chemoembolization (TACE), transarterial radioembolization (TARE), radiofrequency ablation, microwave ablation, cryoablation, chemical ablation, and targeting therapy (e.g., oral sorafenib), or some combination of them[1,2,3,4,5,6]. TAE is not so effective in tumors without rich blood supply due to limitations of the embolization materials. This problem has not received much attention, and there are no relevant reports in literature
Sign-in/Register to view highlights & summary Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
